BLA for subcutaneous formulation of Leqembi® designated for Priority Review in China

Contributed by: PR Newswire

Tags

BioArctic

More Like This

BLA for subcutaneous formulation of Leqembi® accepted in China

Leqembi® Iqlik™ (lecanemab-irmb) supplemental Biologics License Application regarding subcutaneous starting dose granted Priority Review by the US FDA

FDA accepts Biologics License Application for subcutaneous maintenance dosing of Leqembi® (lecanemab-irmb) in the US

Eisai completes rolling BLA submission for subcutaneous maintenance dosing of Leqembi® (lecanemab-irmb) in the US

Eisai initiates rolling Biologics License Application to US FDA for Leqembi® (lecanemab-irmb) for subcutaneous maintenance dosing

Rolling sBLA initiated to the U.S. FDA for Leqembi® Iqlik™ (lecanemab-irmb) as a subcutaneous starting dose for the treatment of early Alzheimer's disease under Fast Track status

Leqembi® approved for the treatment of Alzheimer's disease in China

'LEQEMBI® Intravenous Infusion' approved for the treatment of Alzheimer's disease in Japan